RA Capital

Cellcentric

cellcentric.com

CellCentric is a clinical-stage biotech company focusing on the inhibition of p300/CBP to treat specific cancers, particularly solid tumors. The programme also has potential clinical utility in non-small cell lung, breast, and colon cancer. The company's oral drug, Inobrodib, is currently in Phase I/II clinical trials and aims to address cancers such as multiple myeloma. The company is committed to science-driven solutions for cancer, with a patient-focused approach to novel therapies.